NEO-N BCT 1902

This study aims to find out how well using Nivolumab on its own before starting standard chemotherapy, or starting treatment with Nivolumab at the same time as standard chemotherapy, helps to reduce tumour size before surgery in patients with previously untreated early stage triple negative breast cancer.

Acronym:

NEO-N BCT

ACTRN/NCT /ethics:

ACTRN12619001308189

Scientific title:

A randomised phase II trial evaluating the efficacy of a nivolumab monotherapy lead in “window” or commencement of nivolumab concurrently with paclitaxel and carboplatin as neoadjuvant therapy in early stage triple negative breast cancer

Sponsor / Cooperative group:

Breast Cancer Trials